Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management
The advent of immunotherapy, specifically of immune checkpoint inhibitors (ICIs), for the treatment of solid tumors has deeply transformed therapeutic algorithms in medical oncology. Approximately one-third of patients treated with ICIs may de velop immune-related adverse events, and the gastrointes...
Main Authors: | Maria Terrin, Giulia Migliorisi, Arianna Dal Buono, Roberto Gabbiadini, Elisabetta Mastrorocco, Alessandro Quadarella, Alessandro Repici, Armando Santoro, Alessandro Armuzzi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/14/11504 |
Similar Items
-
Checkpoint Inhibitor-Induced Colitis: An Update
by: Giuseppe Losurdo, et al.
Published: (2023-05-01) -
Interaction between gut microbiota and immune checkpoint inhibitor-related colitis
by: Guanzhou Zhou, et al.
Published: (2022-10-01) -
Microscopic Colitis: Pathogenesis and Diagnosis
by: Busara Songtanin, et al.
Published: (2023-07-01) -
Sphingosine 1-Phosphate Modulation in Inflammatory Bowel Diseases: Keeping Lymphocytes Out of the Intestine
by: Arianna Dal Buono, et al.
Published: (2022-07-01) -
Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib
by: Mark W. D. Sweep, et al.
Published: (2023-06-01)